Navamedic concentrates key resources on the development of its Vitaflo business
Company will initiate a process to move main head office functions to Gothenburg
According to the company, Vitaflo Scandinavia AB has developed positively since the acquisition last year, and it is the Board of Director's opinion that Navamedic's strategic positioning from a one product company to a regional pharmaceutical player has been a success. At the same time, Glucomed has not delivered as expected, and the Board of Directors has decided to focus the future development of the group on Vitaflo Scandinavia AB with main management functions located close to this business line in Sweden and Denmark. The Board of Directors believes that this business area, with a strengthened focus will continue to deliver significant growth both on top line and EBITDA in the next years.
Following the Board's decisions and the structural changes to be implemented, CEO Øyvind W. Brekke has decided to resign from his position. He will assist the company for some time focusing on Glucomed issues. The recruitment process for a new CEO starts immediately. The current CFO, Bernt-Olav Røttingsnes, will hold both CEO and CFO positions in the interim period.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.